거세저항성 전립선암 시장 규모, 점유율, 동향 분석 보고서 : 치료법별, 지역별, 부문별 예측(2025-2030년)

Castrate-resistant Prostate Cancer Market Growth & Trends:

The global castrate-resistant prostate cancer market size is expected to reach USD 21.44 billion in 2030 and is projected to grow at a CAGR of 8.7% from 2025 to 2030. This growth is driven by the rising global burden of castrate-resistant prostate cancer and unhealthy lifestyle.

In addition, the anticipated launch of new products and rising awareness of prostate cancer are likely to enhance the growth rate of the market over the forecast period. Moreover, the growing adoption of novel drugs and strong pipeline are factors likely to accelerate market growth during the forecast period.

The hormonal therapy segment dominated the global castrate-resistant prostate cancer market with a revenue share of 42.2% in 2024 due to the effectiveness of advanced hormonal therapies in managing CRPC. The segment is driven by increasing market penetration of Xtandi (enzalutamide) and the launch of Erleada (apalutamide) in the U.S., Europe, and Japan. Furthermore, the development and approval of an additional indication of Xtandi are driving the segment growth. In addition, immunotherapy is estimated to be the fastest-growing segment due to the presence of strong product pipeline drugs, which are projected to be launched during the forecast period.

North America's dominant share is attributable to high disease burden, technological advancements, proactive government measures, increased consumer awareness about the disease, and improvements in healthcare infrastructure. The presence of key players in this region is a key factor in boosting the growth of the market in the region. In addition, developing countries such as India and China are witnessing a high incidence of the disease that has resulted in an increase in the demand for improved therapeutics, an increase in healthcare expenditure, and a rise in government funding for oncology and other research activities. Thus, these factors are expected to drive the market in the Asia Pacific during the forecast period.

The presence of prominent players such as Sanofi; Johnson and Johnson Services, Inc.; Pfizer, Inc.; Astellas Pharma, Inc.; and Bayer AG in this market space significantly diminishes the opportunities of a new entry as it is difficult to match the high capital requirements. Key players are investing highly in the development of new molecules to maintain their presence in the market and acquire market share.

Castrate-resistant Prostate Cancer Market Report Highlights:

• The hormonal therapy segment dominated the global castrate-resistant prostate cancer market with a revenue share of 42.2% in 2024 due to the effectiveness of advanced hormonal therapies in managing CRPC.
• The immunotherapy segment is projected to grow at a CAGR of 11.9% from 2025 to 2030, driven by the increasing recognition of immunotherapy's potential to provide durable responses and improve overall survival in CRPC patients
• North America held the largest revenue share of 47.9% of the global castrate-resistant prostate cancer market in 2024
• Asia Pacific castrate-resistant prostate cancer market is anticipated to grow fastest throughout the forecast period, driven by the increasing prevalence of prostate cancer in densely populated countries such as China, Japan, and India

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Therapy
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Castrate-resistant Prostate Cancer Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTLE Analysis

Chapter 4. Castrate-resistant Prostate Cancer Market: Therapy Business Analysis

• 4.1. Therapy Market Share, 2024 & 2030
• 4.2. Therapy Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Therapy, 2018 to 2030 (USD Million)
• 4.4. Chemotherapy
  • 4.4.1. Chemotherapy market, 2018 - 2030 (USD Million)
• 4.5. Hormonal Therapy
  • 4.5.1. Hormonal Therapy market, 2018 - 2030 (USD Million)
• 4.6. Immunotherapy
  • 4.6.1. Immunotherapy market, 2018 - 2030 (USD Million)
• 4.7. Radiotherapy
  • 4.7.1. Radiotherapy market, 2018 - 2030 (USD Million)

Chapter 5. Castrate-resistant Prostate Cancer Market: Region Estimates & Trend Analysis by Therapy

• 5.1. Region Market Share Analysis, 2024 & 2030
• 5.2. Region Market Dashboard
• 5.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 5.4. North America
  • 5.4.1. North America castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.4.2. U.S.
    • 5.4.2.1. Key country dynamics
    • 5.4.2.2. Regulatory framework
    • 5.4.2.3. Competitive insights
    • 5.4.2.4. U.S. castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.4.3. Canada
    • 5.4.3.1. Key country dynamics
    • 5.4.3.2. Regulatory framework
    • 5.4.3.3. Competitive insights
    • 5.4.3.4. Canada castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.4.4. Mexico
    • 5.4.4.1. Key country dynamics
    • 5.4.4.2. Regulatory framework
    • 5.4.4.3. Competitive insights
    • 5.4.4.4. Mexico castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.5. Europe
  • 5.5.1. Europe castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5.2. UK
    • 5.5.2.1. Key country dynamics
    • 5.5.2.2. Regulatory framework
    • 5.5.2.3. Competitive insights
    • 5.5.2.4. UK castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5.3. Germany
    • 5.5.3.1. Key country dynamics
    • 5.5.3.2. Regulatory framework
    • 5.5.3.3. Competitive insights
    • 5.5.3.4. Germany castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5.4. France
    • 5.5.4.1. Key country dynamics
    • 5.5.4.2. Regulatory framework
    • 5.5.4.3. Competitive insights
    • 5.5.4.4. France castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5.5. Italy
    • 5.5.5.1. Key country dynamics
    • 5.5.5.2. Regulatory framework
    • 5.5.5.3. Competitive insights
    • 5.5.5.4. Italy castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5.6. Spain
    • 5.5.6.1. Key country dynamics
    • 5.5.6.2. Regulatory framework
    • 5.5.6.3. Competitive insights
    • 5.5.6.4. Spain castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5.7. Norway
    • 5.5.7.1. Key country dynamics
    • 5.5.7.2. Regulatory framework
    • 5.5.7.3. Competitive insights
    • 5.5.7.4. Norway castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5.8. Sweden
    • 5.5.8.1. Key country dynamics
    • 5.5.8.2. Regulatory framework
    • 5.5.8.3. Competitive insights
    • 5.5.8.4. Sweden castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5.9. Denmark
    • 5.5.9.1. Key country dynamics
    • 5.5.9.2. Regulatory framework
    • 5.5.9.3. Competitive insights
    • 5.5.9.4. Denmark castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.6. Asia Pacific
  • 5.6.1. Asia Pacific castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.6.2. Japan
    • 5.6.2.1. Key country dynamics
    • 5.6.2.2. Regulatory framework
    • 5.6.2.3. Competitive insights
    • 5.6.2.4. Japan castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.6.3. China
    • 5.6.3.1. Key country dynamics
    • 5.6.3.2. Regulatory framework
    • 5.6.3.3. Competitive insights
    • 5.6.3.4. China castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.6.4. India
    • 5.6.4.1. Key country dynamics
    • 5.6.4.2. Regulatory framework
    • 5.6.4.3. Competitive insights
    • 5.6.4.4. India castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.6.5. Thailand
    • 5.6.5.1. Key country dynamics
    • 5.6.5.2. Regulatory framework
    • 5.6.5.3. Competitive insights
    • 5.6.5.4. Thailand castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.6.6. South Korea
    • 5.6.6.1. Key country dynamics
    • 5.6.6.2. Regulatory framework
    • 5.6.6.3. Competitive insights
    • 5.6.6.4. South Korea castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.6.7. Australia
    • 5.6.7.1. Key country dynamics
    • 5.6.7.2. Regulatory framework
    • 5.6.7.3. Competitive insights
    • 5.6.7.4. Australia castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.7. Latin America
  • 5.7.1. Latin America castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.7.2. Brazil
    • 5.7.2.1. Key country dynamics
    • 5.7.2.2. Regulatory framework
    • 5.7.2.3. Competitive insights
    • 5.7.2.4. Brazil castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.7.3. Argentina
    • 5.7.3.1. Key country dynamics
    • 5.7.3.2. Regulatory framework
    • 5.7.3.3. Competitive insights
    • 5.7.3.4. Argentina castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.8. Middle East & Africa
  • 5.8.1. Middle East & Africa castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.8.2. South Africa
    • 5.8.2.1. Key country dynamics
    • 5.8.2.2. Regulatory framework
    • 5.8.2.3. Competitive insights
    • 5.8.2.4. South Africa castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.8.3. Saudi Arabia
    • 5.8.3.1. Key country dynamics
    • 5.8.3.2. Regulatory framework
    • 5.8.3.3. Competitive insights
    • 5.8.3.4. Saudi Arabia castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.8.4. UAE
    • 5.8.4.1. Key country dynamics
    • 5.8.4.2. Regulatory framework
    • 5.8.4.3. Competitive insights
    • 5.8.4.4. UAE castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.8.5. Kuwait
    • 5.8.5.1. Key country dynamics
    • 5.8.5.2. Regulatory framework
    • 5.8.5.3. Competitive insights
    • 5.8.5.4. Kuwait castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Participant Overview
• 6.2. Company Market Position Analysis
• 6.3. Company Categorization
• 6.4. Strategy Mapping
• 6.5. Company Profiles/Listing
  • 6.5.1. Sanofi
    • 6.5.1.1. Overview
    • 6.5.1.2. Financial performance
    • 6.5.1.3. Material benchmarking
    • 6.5.1.4. Strategic initiatives
  • 6.5.2. Johnson & Johnson Services, Inc.
    • 6.5.2.1. Overview
    • 6.5.2.2. Financial performance
    • 6.5.2.3. Material benchmarking
    • 6.5.2.4. Strategic initiatives
  • 6.5.3. Pfizer, Inc.
    • 6.5.3.1. Overview
    • 6.5.3.2. Financial performance
    • 6.5.3.3. Material benchmarking
    • 6.5.3.4. Strategic initiatives
  • 6.5.4. Astellas Pharma, Inc.
    • 6.5.4.1. Overview
    • 6.5.4.2. Financial performance
    • 6.5.4.3. Material benchmarking
    • 6.5.4.4. Strategic initiatives
  • 6.5.5. Bayer AG
    • 6.5.5.1. Overview
    • 6.5.5.2. Financial performance
    • 6.5.5.3. Material benchmarking
    • 6.5.5.4. Strategic initiatives